Acquired Resistance to EGFR-TKI in the Uncommon EGFR Mutation, G719S

被引：0
|
作者：
Osoegawa, A. [1 ]
Hashimoto, T. [1 ]
Takumi, Y. [1 ]
Kobayashi, R. [1 ]
Miyawaki, M. [1 ]
Takeuchi, H. [1 ]
Okamoto, T. [1 ]
Sugio, K. [1 ]
机构：
[1] Oita Univ, Fac Med, Dept Thorac & Breast Surg, Yufu, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
Acquired resistance; EGFR-TKI; PTEN;
D O I：
10.1016/j.jtho.2017.09.1568
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.02-039
引用
下载
收藏
页码：S2251 / S2251
页数：1
相关论文
共 50 条
  • [41] SLK Causes Resistance to EGFR-TKI in Lung Cancer
    Ashraf, K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2371 - S2372
  • [42] EGFR-TKI FOR LUNG CANCER
    Bai, Chunxue
    RESPIROLOGY, 2010, 15 : 23 - 23
  • [43] EGFR-TKI FOR EGFR MUTATED NSCLC: NEW EVIDENCE
    Okamoto, I.
    ANNALS OF ONCOLOGY, 2010, 21 : 40 - 40
  • [44] Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
    Wang, Wenxian
    Wang, Hong
    Lu, Peihua
    Yu, Zongyang
    Xu, Chunwei
    Zhuang, Wu
    Song, Zhengbo
    JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17 (1)
  • [45] Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
    Wenxian Wang
    Hong Wang
    Peihua Lu
    Zongyang Yu
    Chunwei Xu
    Wu Zhuang
    Zhengbo Song
    Journal of Translational Medicine, 17
  • [46] EGFR-TKI rechallenged treatment combined with apatinib in non-small cell lung cancer with EGFR-TKI resistance.
    Liang, Li
    Li, Fang
    Cao, Baoshan
    Zhang, Zhaohui
    Zhu, Xiang
    Wang, Jiadong
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [47] The mutation profile of genes related to primary resistance to EGFR-TKI in early NSCLC.
    Ye, Jiangang
    Zhang, Qi
    Zhang, Xing
    Qin, Huijuan
    Tian, Minqi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] Dramatical Intracranial Response to Osimertinib in Patient Harbouring the Uncommum EGFR G719S/L861Q Mutation
    Alessi, J. V.
    Ribeiro, M.
    Katz, A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S858 - S858
  • [49] Molecular Divergence upon EGFR-TKI Resistance Could Be Dependent on the Exon Location of the Original EGFR-Sensitizing Mutation
    Serna-Blasco, Roberto
    Sanchez-Herrero, Estela
    Robado de Lope, Lucia
    Sanz-Moreno, Sandra
    Rodriguez-Festa, Alejandro
    Ares-Trotta, Dunixe
    Cruz-Bermudez, Alberto
    Franco, Fabio
    Sanchez-Hernandez, Alfredo
    de Julian Campayo, Maria
    Garcia-Giron, Carlos
    Domine, Manuel
    Blasco, Ana
    Sanchez, Jose M.
    Oramas, Juana
    Bosch-Barrera, Joaquim
    Sala, Maria A.
    Sereno, Maria
    Romero, Atocha
    Provencio, Mariano
    CANCERS, 2022, 14 (18)
  • [50] Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance
    Tian, R.
    ANNALS OF ONCOLOGY, 2021, 32 : S980 - S981
12345